Consistent with this notion, the survivin siRNA approach was used throughout the history of survivin studies [114–118]; the survivin siRNA studies in recent years show a clear trend of developing and using various new delivery technologies of survivin siRNA with or without combination of a cancer drug for therapeutics in vitro [119–123] and in vivo [124–131]. The gene discussed is BIRC5; the disease is cancer.